Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.

Abstract: A selectable output current mirror may include a reference leg configured to generate a reference current, an output leg electrically coupled to the reference leg in a manner such that the output leg is configured to generate at an output of the output leg an output current proportional to the reference current, wherein the output leg comprises an output leg transistor, a drain path switch coupled between a first non-gate terminal of the output leg transistor and the output of the output leg, and a series combination of a degeneration resistor and a degeneration path switch coupled between a second non-gate terminal of the output leg transistor and a voltage source to the selectable output current mirror.

Abstract: A selectable output current mirror may include a reference leg configured to generate a reference current, an output leg electrically coupled to the reference leg in a manner such that the output leg is configured to generate at an output of the output leg an output current proportional to the reference current, wherein the output leg comprises an output leg transistor, a drain path switch coupled between a first non-gate terminal of the output leg transistor and the output of the output leg, and a series combination of a degeneration resistor and a degeneration path switch coupled between a second non-gate terminal of the output leg transistor and a voltage source to the selectable output current mirror.

Abstract: Disclosed are dosage forms and methods comprising compounds of Formula (I) and Formula (II). More particularly, disclosed are dosage forms, methods, and new uses of compounds of Formula (I) and Formula (II) that substantially reduce or substantially eliminate certain side effects of the compounds of Formula (I) and Formula (II) when dosed to a patient.